Tuesday, March 24, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025
  • Surveys

    Surveys

    Public Sentiment on the Future of Peptides and Hormone Therapies in U.S. Medicine

    Public Sentiment on the Future of Peptides and Hormone Therapies in U.S. Medicine

    March 17, 2026
    Perceptions of Viral Wellness Practices on Social Media: A Likert-Scale Survey for Informed Readers

    Perceptions of Viral Wellness Practices on Social Media: A Likert-Scale Survey for Informed Readers

    March 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    The Hidden Costs Employers Don’t See in Traditional Health Plans

    The Hidden Costs Employers Don’t See in Traditional Health Plans

    March 22, 2026
    The Impact of COVID-19 on Patient Trust

    The Impact of COVID-19 on Patient Trust

    March 3, 2026
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025
  • Surveys

    Surveys

    Public Sentiment on the Future of Peptides and Hormone Therapies in U.S. Medicine

    Public Sentiment on the Future of Peptides and Hormone Therapies in U.S. Medicine

    March 17, 2026
    Perceptions of Viral Wellness Practices on Social Media: A Likert-Scale Survey for Informed Readers

    Perceptions of Viral Wellness Practices on Social Media: A Likert-Scale Survey for Informed Readers

    March 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Perspectives

How Pet Cancer Data Sheds Light on Human Cancers

Daily Remedy by Daily Remedy
April 3, 2024
in Perspectives
0
How Pet Cancer Data Sheds Light on Human Cancers

How pet cancer data sheds light on human cancers – and speeds the development of new treatments

Dog Running
Dogs are pets in nearly 50 million U.S. homes.
zhao hui/500Px Plus via Getty Images

Rodney Lee Page, Colorado State University

Stunning advances have happened in medicine since President Richard Nixon declared the “war on cancer” just over a half-century ago.

But that progress is only the beginning. More is expected in the coming years and decades, particularly following President Biden’s recent announcement of a new “cancer moonshot” initiative, coupled with a pledge to “end cancer as we know it.”

One way to help make that happen is through the study of cats and dogs. As a professor of oncology and doctor of veterinary medicine who has been researching cancer in dogs for more than 40 years, I learned long ago that companion animals can teach us an enormous amount about how to prevent and treat cancer in people.

There are many reasons why this is true. Domesticated cats and dogs share approximately 85% of the same DNA as humans. And because both have been intimately associated with people for more than 10,000 years, they have become susceptible to some of the same diseases.

A tabby cat with a brown nose and green eyes looks at the camera.
Exposure to tobacco smoke can cause cancer in cats and dogs.
Lysandra Cook/Moment via Getty Images

Remarkable similarities in cats, dogs and people

Over decades, researchers have accumulated what is now a treasure trove of cancer data on companion animals. This data holds clues – and perhaps, answers – to how and why pets can get cancer, and how to keep it in check or get rid of it.

But because of the remarkable similarities in the biology and habitats of cats, dogs and people, it’s possible researchers can also extract this data on pets and extrapolate it to humans. Therein lies the opportunity to discover biomedical innovations that benefit not only your pet, but you as well.

This approach cuts by decades the amount of time it takes for data to come in. Consider that veterinarians observe and care for cats and dogs as they age and die over a life span of roughly 10 to 15 years. In comparison, gathering similar data from humans over a lifetime takes from 60 to 100 years.

You may wonder if the same information could be gleaned from laboratory animals. After all, scientists have been obtaining important data from them for decades to develop new products. But cancer is induced in lab animals artificially, primarily through surgeries or injections; companion animals “naturally” develop disease, and data from them reflect more realistic estimates when serving as precursors to investigations in humans.

Dogs and cats as canaries in the coal mine

Cancer is a leading cause of death for cats and dogs. As with people, the disease develops over a long period of time, and the same conditions that create cancer in humans also apply to them.

Here are some examples: Scientists have long noted the similarities in mutations and biological changes in dogs and people with melanoma, lymphoma and lung cancers. A growing segment of veterinarians, human medical doctors and cancer scientists are using these shared characteristics to develop improved therapeutics for pet dogs with cancer. Many researchers believe this will help them develop effective treatments for humans as well.

Studies show that asbestos exposure can lead to mesothelioma, a malignant tumor that forms on the lining of tissues throughout the body in both dogs and humans. Tobacco smoke can cause lung cancer in humans, lymphoma in cats and nasal cancers in dogs. Learning how to lessen toxin exposure in companion animals could speed up the use of similar strategies to keep humans healthy.

Work is underway to make this happen. In one study, researchers strapped silicon sensors to people and their pets to measure their exposure levels to pesticides and herbicides in the home and yard. The exposure levels between humans and their pets were strikingly similar. This study suggests our pets may serve as harbingers of harmful environmental exposures – the so-called canary in the coal mine.

Scientists are now starting to integrate the millions of human and canine datasets now available and compare them across species. The rapid and recent development of genetic sequencing technologies, along with the proliferation of electronic medical records, has also been tremendously helpful.

These factors will greatly accelerate significant insights into cancer risk factors for both companion animals and people. Already, large population studies of dogs have begun, with researchers collecting the animal’s genetic, environmental, lifestyle and nutritional information.

By watching your pet closely, you may be able to detect signs of cancer in its early stages.

The bone cancer connection

As previously noted, traditional lab animals don’t always make the best subjects for cancer research. The immune systems of mice and rats, for instance, are not as complex as that of humans; those of dogs and cats are far more like our own.

One example: Researchers combined a blood pressure medication, already generically available for humans and dogs, with a chemotherapeutic agent, also approved by the Food and Drug Administration for humans and dogs. Then they studied the repurposed product on pet dogs with bone cancer. The results were so positive that doctors initiated the same protocol in children with bone cancer. That clinical study is not yet far enough along to draw any conclusions.

But the proposition makes sense. Bone cancer in humans and dogs is genetically indistinguishable. If this approach works, it could cut by years, and with far less cost, the time it takes to develop a pharmaceutical product to treat children with bone cancer.

A rule of thumb: The traditional pipeline for a new cancer drug is at least 10 years at a cost of billions of dollars. But the bone cancer clinical trial on children began within five years – and cost US$2 million.

[Over 150,000 readers rely on The Conversation’s newsletters to understand the world. Sign up today.]

What’s next

The people-pet connection is more than just the similarity in species. An extensive veterinary medical infrastructure now exists to support cats and dogs during cancer management. An ever-burgeoning technology and an abundance of data that crosses disciplines are there for the taking.

However, gaps still exist in our knowledge, particularly regarding our understanding of the immune system of companion animals. Additionally, the funding available to conduct clinical studies in companion animals is severely limited. Support from the National Institutes of Health, however, has been earmaked to overcome at least some of these obstacles.

When science learns more about how to prevent and treat cancer in our pets, it’s likely that we will minimize the burden of cancer for all species.

Rodney Lee Page, Professor of Oncology, Colorado State University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

ShareTweet
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

summary

This episode explores deceptive pricing strategies in the GLP-1 medication market, highlighting how healthcare consumerism influences patient decisions and how to recognize and protect against misleading practices.

 key  topics

Deceptive pricing strategies in healthcare
The role of brand perception and pricing manipulation
The concept of drip pricing and hidden costs
The rise of healthcare consumerism and patient agency
Strategies for patients to identify and avoid deceptive practices

Chapters

00:00 The Evolution of the GLP-1 Telemedicine Market
01:12 How Pricing Is Obscured and Perceived Discounts Are Created
02:11 TrumpRx: Coupon Aggregator or Discount Store?
03:12 Why Price Deception Thrives in Healthcare
04:12 The Membership Fee Illusion and Hidden Costs
05:10 Brand Recognition and Drip Pricing Strategies
06:17 The Impact of Brand and Anchor Pricing on Perceived Value
07:16 The Role of Price Drip Strategies in Healthcare Pricing
08:15 The Rise of Healthcare Consumerism and Patient Agency
09:14 How to Protect Yourself from Deceptive Pricing Practices
10:09 Conclusion: Empowering Patients in a Complex Pricing Landscape
Unmasking Deceptive Pricing in Healthcare: What Patients Need to Know
YouTube Video zZgo1nLZVrY
Subscribe

Policy Shift in Peptide Regulation

Clinical Reads

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

by Daily Remedy
March 1, 2026
0

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • The Grey Market of Weight Loss: How Compounded GLP-1 Medications Continue Despite FDA Crackdowns

    The Grey Market of Weight Loss: How Compounded GLP-1 Medications Continue Despite FDA Crackdowns

    0 shares
    Share 0 Tweet 0
  • From Patient Advocate to Subject Matter Expert

    2 shares
    Share 0 Tweet 0
  • A Generation in Distress: New CDC Findings Reveal Worsening Mental Health Among Teen Girls

    0 shares
    Share 0 Tweet 0
  • The Market Failure Inside the Petri Dish

    0 shares
    Share 0 Tweet 0
  • The Glycemic Mirror

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy